{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:41:57Z","timestamp":1794408117723,"version":"4.9.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007053","name":"Korea Institute of Energy Technology Evaluation and Planning","doi-asserted-by":"crossref","award":["20227410100050"],"award-info":[{"award-number":["20227410100050"]}],"id":[{"id":"10.13039\/501100007053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"crossref","award":["RS-2023-00240003"],"award-info":[{"award-number":["RS-2023-00240003"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"crossref","award":["RS-2023-00257618"],"award-info":[{"award-number":["RS-2023-00257618"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2024-00453521"],"award-info":[{"award-number":["RS-2024-00453521"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Basic Science Research Program through NRF","award":["NRF-2022R1H1A2092091"],"award-info":[{"award-number":["NRF-2022R1H1A2092091"]}]},{"name":"Korea Health Industry Development Institute (KHIDI) \u2013 Korea Health Technology R&D Project","award":["RS-2023-KH134708"],"award-info":[{"award-number":["RS-2023-KH134708"]}]},{"name":"Korea Dementia Research Center (KDRC) \u2013 Korea Dementia Research Project","award":["RS-2021-KH112636"],"award-info":[{"award-number":["RS-2021-KH112636"]}]},{"name":"National Research Council of Science and Technology (NST) \u2013 Aging Convergence Research Center","award":["CRC22013-600"],"award-info":[{"award-number":["CRC22013-600"]}]},{"name":"Institute of Information and Communications Technology Planning and Evaluation","award":["2022-0-00448"],"award-info":[{"award-number":["2022-0-00448"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-00743-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:59:58Z","timestamp":1751399998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Machine learning model for predicting Amyloid-\u03b2 positivity and cognitive status using early-phase 18F-Florbetaben PET and clinical features"],"prefix":"10.1038","volume":"15","author":[{"given":"Dong Hyeok","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Jeon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"743_CR1","doi-asserted-by":"crossref","unstructured":"Association As. Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 14, 367\u2013429 (2018).","DOI":"10.1016\/j.jalz.2018.02.001"},{"key":"743_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2018.07.216","volume":"15","author":"KB Rajan","year":"2019","unstructured":"Rajan, K. B. et al. Prevalence and incidence of clinically diagnosed Alzheimer\u2019s disease dementia from 1994 to 2012 in a population study. Alzheimers Dement. 15, 1\u20137 (2019).","journal-title":"Alzheimers Dement."},{"key":"743_CR3","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/molecules27041210","volume":"27","author":"C Ma","year":"2022","unstructured":"Ma, C., Hong, F. & Yang, S. Amyloidosis in Alzheimer\u2019s disease: pathogeny, etiology, and related therapeutic directions. Molecules 27, 1210 (2022).","journal-title":"Molecules"},{"key":"743_CR4","doi-asserted-by":"publisher","first-page":"12841","DOI":"10.3390\/ijms232112841","volume":"23","author":"P Rawat","year":"2022","unstructured":"Rawat, P. et al. Phosphorylated Tau in Alzheimer\u2019s disease and other Tauopathies. Int. J. Mol. Sci. 23, 12841 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"743_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack, C. R. Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 9, 119\u2013128 (2010).","journal-title":"Lancet Neurol."},{"key":"743_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/jnc.13887","volume":"140","author":"G Yamin","year":"2017","unstructured":"Yamin, G. & Teplow, D. B. Pittsburgh Compound-B (PiB) binds amyloid \u03b2\u2010protein protofibrils. J. Neurochem. 140, 210\u2013215 (2017).","journal-title":"J. Neurochem"},{"key":"743_CR7","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jalz.2012.10.007","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson, K. A. et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer\u2019s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 9, S72\u2013S83 (2013).","journal-title":"Alzheimers Dement."},{"key":"743_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe, C. C. et al. Imaging of amyloid \u0392 in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7, 129\u2013135 (2008).","journal-title":"Lancet Neurol."},{"key":"743_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jalz.2015.05.018","volume":"11","author":"DR Thal","year":"2015","unstructured":"Thal, D. R. et al. [18F] flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer\u2019s disease: specific detection of advanced phases of amyloid-\u03b2 pathology. Alzheimers Dement. 11, 975\u2013985 (2015).","journal-title":"Alzheimers Dement."},{"key":"743_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jnc.13838","volume":"139","author":"J Pannee","year":"2016","unstructured":"Pannee, J. et al. Reference measurement procedure for CSF amyloid beta (A\u03b2) 1\u201342 and the CSF A\u03b21\u201342\/A\u03b21\u201340 ratio\u2013a cross-validation study against amyloid PET. J. Neurochem. 139, 651\u2013658 (2016).","journal-title":"J. Neurochem"},{"key":"743_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13550-021-00798-3","volume":"11","author":"S Kim","year":"2021","unstructured":"Kim, S. et al. Deep learning-based amyloid PET positivity classification model in the Alzheimer\u2019s disease continuum by using 2-[18F] FDG PET. EJNMMI Res. 11, 56 (2021).","journal-title":"EJNMMI Res."},{"key":"743_CR12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/diagnostics12040933","volume":"12","author":"P Alongi","year":"2022","unstructured":"Alongi, P. et al. Radiomics analysis of brain [18F] FDG PET\/CT to predict Alzheimer\u2019s disease in patients with amyloid PET positivity: a preliminary report on the application of SPM cortical segmentation, pyradiomics and machine-learning analysis. Diagnostics 12, 933 (2022).","journal-title":"Diagnostics"},{"key":"743_CR13","doi-asserted-by":"publisher","first-page":"108098","DOI":"10.1016\/j.cmpb.2024.108098","volume":"247","author":"R Rasi","year":"2024","unstructured":"Rasi, R. & Guvenis, A. Alzheimer\u2019s disease neuroimaging initiative. Predicting amyloid positivity from FDG-PET images using radiomics: a parsimonious model. Comput. Methods Programs Biomed. 247, 108098 (2024).","journal-title":"Comput. Methods Programs Biomed."},{"key":"743_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2967\/jnumed.110.083683","volume":"52","author":"PT Meyer","year":"2011","unstructured":"Meyer, P. T. et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11\u00a0C-labeled Pittsburgh compound B. J. Nucl. Med. 52, 393\u2013400 (2011).","journal-title":"J. Nucl. Med."},{"key":"743_CR15","doi-asserted-by":"publisher","first-page":"e0211000","DOI":"10.1371\/journal.pone.0211000","volume":"14","author":"DE Peretti","year":"2019","unstructured":"Peretti, D. E. et al. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer\u2019s disease PET studies. PLoS One. 14, e0211000 (2019).","journal-title":"PLoS One"},{"key":"743_CR16","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s00259-013-2350-x","volume":"40","author":"IT Hsiao","year":"2013","unstructured":"Hsiao, I. T. et al. Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45\/Amyvid) PET. Eur. J. Nucl. Med. Mol. Imaging. 40, 908\u2013920 (2013).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"743_CR17","doi-asserted-by":"crossref","unstructured":"Boccalini, C. et al. Early-phase 18F-Florbetapir and 18F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting. J. Nucl. Med. 64,  jnumed.122.264256 (2022).","DOI":"10.2967\/jnumed.122.264256"},{"key":"743_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"743_CR19","doi-asserted-by":"publisher","first-page":"102773","DOI":"10.1016\/j.nicl.2021.102773","volume":"31","author":"HJ Yoon","year":"2021","unstructured":"Yoon, H. J. et al. Dual-phase 18F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer\u2019s disease. Neuroimage Clin. 31, 102773 (2021).","journal-title":"Neuroimage Clin."},{"key":"743_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel, H. et al. Cerebral amyloid-\u03b2 PET with Florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicenter phase 2 diagnostic study. Lancet Neurol. 10, 424\u2013435 (2011).","journal-title":"Lancet Neurol."},{"key":"743_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.nicl.2017.04.025","volume":"15","author":"S Bullich","year":"2017","unstructured":"Bullich, S. et al. Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. Neuroimage Clin. 15, 325\u2013332 (2017).","journal-title":"Neuroimage Clin."},{"key":"743_CR22","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3348\/jksr.2022.0084","volume":"84","author":"HJ Park","year":"2023","unstructured":"Park, H. J. et al. Prediction of amyloid \u03b2-Positivity with both MRI parameters and cognitive function using machine learning. J. Korean Soc. Radiol. 84, 638 (2023).","journal-title":"J. Korean Soc. Radiol."},{"key":"743_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0306-4522(95)90397-P","volume":"64","author":"TG Ohm","year":"1995","unstructured":"Ohm, T. G. et al. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer\u2019s disease-related neurofibrillary changes. Neuroscience 64, 209\u2013217 (1995).","journal-title":"Neuroscience"},{"key":"743_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-024-01429-4","volume":"16","author":"S Kang","year":"2024","unstructured":"Kang, S. et al. Alteration of medial Temporal lobe metabolism related to Alzheimer\u2019s disease and dementia with lewy bodies. Alzheimers Res. Ther. 16, 89 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"743_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2009.07.003","volume":"63","author":"RA Sperling","year":"2009","unstructured":"Sperling, R. A. et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63, 178\u2013188 (2009).","journal-title":"Neuron"},{"key":"743_CR26","doi-asserted-by":"publisher","first-page":"fcab201","DOI":"10.1093\/braincomms\/fcab201","volume":"3","author":"S Ingala","year":"2021","unstructured":"Ingala, S. et al. Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Commun. 3, fcab201 (2021).","journal-title":"Brain Commun."},{"key":"743_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamaneurol.2020.3780","volume":"78","author":"PS Insel","year":"2021","unstructured":"Insel, P. S. et al. Association between Apolipoprotein E \u03952 vs \u03954, age, and \u03b2-amyloid in adults without cognitive impairment. JAMA Neurol. 78, 229\u2013235 (2021).","journal-title":"JAMA Neurol."},{"key":"743_CR28","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/ene.15775","volume":"30","author":"J Hwang","year":"2023","unstructured":"Hwang, J. et al. Detecting amyloid-\u03b2 positivity using regions of interest from structural magnetic resonance imaging. Eur. J. Neurol. 30, 1574\u20131584 (2023).","journal-title":"Eur. J. Neurol."},{"key":"743_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/ana.23921","volume":"74","author":"D Tosun","year":"2013","unstructured":"Tosun, D. et al. Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Ann. Neurol. 74, 188\u2013198 (2013).","journal-title":"Ann. Neurol."},{"key":"743_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ana.10669","volume":"54","author":"PJ Nestor","year":"2003","unstructured":"Nestor, P. J. et al. Limbic hypometabolism in Alzheimer\u2019s disease and mild cognitive impairment. Ann. Neurol. 54, 343\u2013351 (2003).","journal-title":"Ann. Neurol."},{"key":"743_CR31","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1097\/RLU.0000000000002768","volume":"45","author":"SH Son","year":"2020","unstructured":"Son, S. H. et al. Early-phase 18F-florbetaben PET as an alternative modality for 18F-FDG PET. Clin. Nucl. Med. 45, e8\u2013e14 (2020).","journal-title":"Clin. Nucl. Med."},{"key":"743_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-019-0499-4","volume":"9","author":"F Heeman","year":"2019","unstructured":"Heeman, F. et al. Optimized dual-time-window protocols for quantitative [18F] flutemetamol and [18F] Florbetaben PET studies. EJNMMI Res. 9, 1\u201314 (2019).","journal-title":"EJNMMI Res."},{"key":"743_CR33","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jalz.2019.05.010","volume":"15","author":"J Ottoy","year":"2019","unstructured":"Ottoy, J. et al. 18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer\u2019s disease: validation against 15O-H2O PET. Alzheimers Dement. 15, 1172\u20131182 (2019).","journal-title":"Alzheimers Dement."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00743-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:00:00Z","timestamp":1751400000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00743-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-00743-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21987"}}